Sanofi (SNY) and Earendil Labs have signed a licensing deal for two bispecific antibodies that target autoimmune and inflammatory bowel diseases, Earendil Labs said in a statement Thursday.
Sanofi will gain exclusive global rights to drug candidates HXN-1002 and HXN-1003 once the deal closes, according to the statement.
Earendil will receive an upfront payment of $125 million from Sanofi, it added.
Earendil could earn up to $1.72 billion in development and commercial milestones, including a $50 million payment expected soon after closing, Earendil Labs said.
Earendil is also eligible for tiered sales royalties that start in the high single digits and rise to the low double digits, the statement added.
Sanofi's shares were up about 1.6% in recent trading.
Price: 51.35, Change: +0.79, Percent Change: +1.56
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。